Gilead Sciences, Inc (NASDAQ: GILD) on Friday, soared 8.28% from the previous trading day, before settling in for the closing price of $110.28. Within the past 52 weeks, GILD’s price has moved between $72.43 and $119.96.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -38.13% over the last five years. The company achieved an average annual earnings per share of 75.20%. With a float of $1.24 billion, this company’s outstanding shares have now reached $1.24 billion.
The firm has a total of 17600 workers. Let’s measure their productivity. In terms of profitability, gross margin is 78.29%, operating margin of 28.61%, and the pretax margin is 23.75%.
Gilead Sciences, Inc (GILD) Insider Activity
Observing investor behavior towards Drug Manufacturers – General industry stocks is more important than anything else. The insider ownership of Gilead Sciences, Inc is 0.16%, while institutional ownership is 87.06%. The most recent insider transaction that took place on Jul 28 ’25, was worth 1,139,370. In this transaction Chairman & CEO of this company sold 10,000 shares at a rate of $113.94, taking the stock ownership to the 605,725 shares. Before that another transaction happened on Jul 28 ’25, when Company’s Officer proposed sale 10,000 for $113.94, making the entire transaction worth $1,139,369.
Gilead Sciences, Inc (GILD) Earnings and Forecasts
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported 2.02 earnings per share (EPS) for the period topping the consensus outlook (set at 1.55) by 0.47. Wall Street market experts anticipate that the next fiscal year will bring earnings of 2.13 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 75.20% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 26.41% during the next five years compared to -38.13% drop over the previous five years of trading.
Gilead Sciences, Inc (NASDAQ: GILD) Trading Performance Indicators
Gilead Sciences, Inc (GILD) is currently performing well based on its current performance indicators. A quick ratio of 1.15 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.14. Likewise, its price to free cash flow for the trailing twelve months is 15.81.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 5.03, a number that is poised to hit 2.16 in the next quarter and is forecasted to reach 8.59 in one year’s time.
Technical Analysis of Gilead Sciences, Inc (GILD)
Analysing the last 5-days average volume posted by the [Gilead Sciences, Inc, GILD], we can find that recorded value of 8.3 million was lower than the volume posted last year of 8.42 million. As of the previous 9 days, the stock’s Stochastic %D was 36.69%.
During the past 100 days, Gilead Sciences, Inc’s (GILD) raw stochastic average was set at 92.97%, which indicates a significant increase from 85.21% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 2.68 in the past 14 days, which was lower than the 2.96 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $110.97, while its 200-day Moving Average is $102.48.
